Pinnacle Medicines, a Pioneer of Oral Peptide Therapeutics, Announces Oversubscribed $89 Million Series B Financing to Advance Pipeline into Clinical Trials
Financing co-led by LAV and Foresite Capital with participation from Quan Capital, Hankang Capital, RA Capital Management, Logos…